ライフサイエンスコーパス: 5-HT receptor

1 on by autocrine signalling through the SER-7 5-HT receptor.

2 uptake transporter (SERT) and 15 subtypes of 5-HT receptor.

3 tor antagonist, which has no effect on other 5-HT receptor.

4 HT) release and direct modulation of several 5-HT receptors.

5 nd olfaction through at least four different 5-HT receptors.

6 specially animals expressing only individual 5-HT receptors.

7 n (5-HT), which subsequently act on multiple 5-HT receptors.

8 ments of the pallidum, which express several 5-HT receptors.

9 erived MC (huMC) expressed mRNA for multiple 5-HT receptors.

10 ) for the 5-HT(2) receptor relative to other 5-HT receptors.

11 ffects are mediated by at least 14 different 5-HT receptors.

12 nigra which in turn is mediated via multiple 5-HT receptors.

13 cyclic drugs described as pan-antagonists at 5-HT receptors.

14 tify the determinants of drug recognition in 5-HT receptors.

15 that control the activity of the prefrontal 5-HT receptors.

16 pine is an antagonist of all five Drosophila 5-HT receptors.

17 ndicative of neuroadaptations of presynaptic 5-HT receptors.

18 o ligands directly interacting with specific 5-HT receptors.

19 onin (5-HT) system, including alterations in 5-HT receptors.

20 its actions via ionotropic and metabotropic 5-HT receptors.

21 ors of the 5-HT transporter and a variety of 5-HT receptors.

22 in animals containing null alleles of these 5-HT receptors.

23 -hydroxytryptamine(2A) (5-HT(2A)) serotonin (5-HT) receptor.

24 receptor is the least understood serotonin (5-HT) receptor.

25 n SMC growth and Rho A/ROCK participation in 5-HT receptor 1B/1D-mediated mitogenesis of vascular SMC

26 Ile (INI) of serotonin [5-hydroxytryptamine (5-HT)] receptor 2C (5-HT(2C)R) with Val, Gly, and Val (V

27 yptamine (5-HT), induces apnea via acting on 5-HT receptor 3 (5-HT(3)R) in PCFs, and among the 5-HT(3

28 the serotonin receptor 5-hydroxytryptamine (5-HT) receptor 5-HT2AR.

29 The distribution of the serotonin (5-HT) receptor 5-HT2C mRNA was examined at the single-ce

30 through the serotonin (5-hydroxytryptamine (5-HT)) receptor 5-HT(2A) (ref.

31 yptamine (5-HT)) led to sequestration of the 5-HT receptor (5-HT2AR) into a Rab11-positive juxtanucle

32 , in vivo atlas of four of the human brain's 5-HT receptors (5-HT1A, 5-HT1B, 5-HT2A, and 5-HT4) and t

33 In addition, 5-HT receptors (5-HT2B) were expressed in SPX1a neurons.

34 onin (5-HT) interacts with a wide variety of 5-HT receptors (5-HTR) of which 5-HT2AR plays an importa

35 rlying spasticity, upregulated expression of 5-HT receptors (5-HTR) on the spinal motor neurons due t

36 d arise by either the expression of multiple 5-HT receptors (5-HTRs) on the same cells or by populati

37 ription and translation for each of the five 5-HT receptors (5-HTRs) to identify neurons, based on ce

38 Serotonin (5-hydroxytryptamine, 5-HT) receptors (5-HTRs) play critical roles in brain an

39 were given ketanserin (an antagonist of the 5-HT receptor, 5-HT(2A)) or scopolamine (an antagonist o

40 ne crosstalk is achieved through a serotonin-5-HT receptor 7 (HTR7) signaling axis that ultimately fa

41 tis elegans encodes a new type of ionotropic 5-HT receptor, a 5-HT-gated chloride channel.

42 ing antagonists for the 5-hydroxytryptamine (5-HT) receptor, about 50% of patients given moderately e

43 however, the specific combination of DA and 5-HT receptors activated determined the regional- and ce

44 2/3 antagonism, AMPA receptor potentiation, 5-HT receptor-activating psychedelics, etc.), the sustai

45 e tested the hypothesis that episodic spinal 5-HT receptor activation (without AIH) is sufficient to

46 ause of this effect is through inhibition of 5-HT receptor activation by quinine, as we observed here

47 Thus, episodic spinal 5-HT receptor activation is sufficient to elicit pMF by

48 at the facilitation of TRPV1 by metabotropic 5-HT receptor activation may contribute to hypersensitiv

49 Since 5-HT receptor activation stimulates NADPH oxidase activi

50 he effect of serotonin (5-hydroxytryptamine, 5-HT) receptor activation on segmental and descending mo

51 othesis that serotonin [5-hydroxytryptamine (5-HT)] receptor activation enhances TRPV1 function in mo

52 (ketanserin tartrate), and the non-selective 5-HT receptor agents, 2-(1-piperazinyl)quinoline dimalea

53 Responses to 5-HT receptor agonist challenge were assessed by local c

54 .5, 1.0, or 4.0 microg/0.5 microl/side), the 5-HT receptor agonist EMD 386088 (at 0.0, 1.0, and 4.0 m

55 5-HT and 5-HT receptor agonists depressed the firing rate of both

56 he possibility that hepatic-targeted 5-HT or 5-HT receptor agonists might reduce postprandial hypergl

57 l experiments examined the impact of various 5-HT receptor agonists on NPY stimulated eating and alte

58 The influence of 5-HT receptor agonists on the expression of BDNF in brai

59 Administration of selective DA and 5-HT receptor agonists was also sufficient to induce pMe

60 ior hypothalamus (AH) and the interaction of 5-HT receptor agonists with arginine vasopressin (AVP) i

61 3.5 nmol), we found that the directly acting 5-HT receptor agonists, 1-[3-(trifluoromethyl)phenyl]pip

62 ons after activation by 5-hydroxytryptamine (5-HT) receptor agonists.

63 5-ht(5A) is among the recently cloned, novel 5-HT receptors and currently under investigation to iden

64 lating SCN circadian rhythm by activation of 5-HT receptors and opening of a potassium channel.

65 e spatial relationships between postsynaptic 5-HT receptors and presynaptic 5-HT neurons, consistent

66 100beta, we investigated the codependence of 5-HT receptors and SERT in regulating S100A4/Mts1 in hum

67 ctivation of spinal excitatory amino acid or 5-HT receptors and that concomitant activation of spinal

68 stimulates smooth muscle cell growth through 5-HT receptors and the 5-HT transporter (5-HTT), and has

69 hanges in the regional density of binding to 5-HT receptors and transporters and the levels of trypto

70 Serotonin (5-HT) receptors and N-methyl-D-aspartate receptors (NMDA

71 Serotonin (5-HT) receptors and NMDA receptors (NMDARs) have been im

72 tor (5-HT7R) is the most recently discovered 5-HT receptor, and its physiologic and possible pathophy

73 Serotonin (5-HT) receptor antagonism did not contribute to proprano

74 Pretreatment with a 5-HT receptor antagonist partially inhibited IL-6 increa

75 nhibitor (SSRI), or 2 microM methiothepin, a 5-HT receptor antagonist, increased microdialysate conce

76 tified the serotonin (5-hydroxytryptamine or 5-HT) receptor antagonist metitepine as a potent anorect

77 taken orally every 8 h; any first-generation 5-HT-receptor antagonist (except palonosetron) taken as

78 eceive doxorubicin were given a short-acting 5-HT-receptor antagonist and dexamethasone before doxoru

79 We aimed to assess whether a 5-HT-receptor antagonist was more effective than was pro

80 5-HT receptor antagonists (SDZ205-557, granisetron, meth

81 We conclude that PAF and 5-HT receptor antagonists accelerate DNA repair caused b

82 5-HT receptor antagonists and agonists were given as dru

83 Various 5-HT receptor antagonists inhibited cAMP production indu

84 Injecting PAF and 5-HT receptor antagonists into UV-irradiated Xeroderma p

85 The 5-HT receptor antagonists metergoline (non-specific rece

86 gonists but is inhibited by the metabotropic 5-HT receptor antagonists mianserin and methiothepin.

87 in UV-irradiated mice injected with PAF and 5-HT receptor antagonists.

88 8-oxo-deoxyguanosine was reduced by PAF and 5-HT receptor antagonists.

89 ed DNA synthesis, was accelerated by PAF and 5-HT receptor antagonists.

90 recordings, and iontophoresis of serotonin (5-HT) receptor antagonists in the mouse visual cortex.

91 telet-activating factor (PAF) and serotonin (5-HT) receptor antagonists, regulate DNA repair.

92 Psychotropic drugs, 5-hydroxytryptamine (5-HT)-receptor antagonists, peppermint oil, and Chinese

93 ), as did 179 (79%) of 226 patients assigned 5-HT-receptor antagonists (3.29 [3.09-3.48]) and 179 (82

94 less delayed nausea than did those allocated 5-HT-receptor antagonists (p=0.05, t test) and those all

95 Attenuation of 5-HT binding by 5-HT-receptor antagonists and 5-HT-uptake inhibitors doe

96 Short-acting 5-HT-receptor antagonists are no better than is prochlor

97 Evidence for the efficacy of 5-HT-receptor antagonists seems favorable, although more

98 Because none of these 5-HT receptors appear to be expressed in the ASH sensory

99 with pertussis toxin (PTX), indicating that 5-HT receptors are coupled to Ca(V)2.2 via Galpha (i/o)

100 In summary, all three 5-HT receptors are equally represented in Vg and the DRG

101 arget 5-HT(1A), 5-HT(1D), 5-HT(1E) and other 5-HT receptors are used to treat numerous disorders(4).

102 tropic and metabotropic 5-hydroxytryptamine (5-HT) receptors are expressed on whisker Abeta-afferent

103 Because dopamine (DA) and serotonin (5-HT) receptors are implicated in impulsive behavior, se

104 y 5-HT(2A)Rs and 5-HT(2C)Rs implicates these 5-HT receptors as important in the behavioral outcomes o

105 m facilitation and require the activation of 5-HT receptors at multiple sites.

106 distribution of post-synaptically expressed 5-HT receptors better correlates with DRN 5-HT functiona

107 Previously, abnormalities in 5-HT receptor binding in the medullae of infants dying f

108 A significant reduction in 5-HT receptor binding measured with 3H-LSD was observed

109 rmalities of serotonin (5-hydroxytryptamine [5-HT]) receptor binding in regions of the medulla oblong

110 nteric artery that follows the activation of 5-HT receptors, but not alpha 1-receptors, involves phos

111 at concomitant activation of spinal NMDA and 5-HT receptors can act synergistically to markedly incre

112 that combinatorial signaling through DA and 5-HT receptors can regulate the brain region- and cell-t

113 l and some clinical evidence that effects on 5-HT receptors contribute to the low risk of producing e

114 we examined the developmental regulation of 5-HT receptors controlling the excitability of pyramidal

115 g effects of serotonin, mediated by distinct 5-HT receptors, could explain why drugs targeting seroto

116 This study also shows that different 5-HT receptors coupled to these proteins can show a wide

117 ug intake, genetically predisposed irregular 5-HT receptor density, or change in sensory bombardment

118 episodes of enhanced 5-HT release leading to 5-HT receptor desensitization.

119 d characterized a deregulation of prefrontal 5-HT receptor electrophysiological signaling in mouse mo

120 Activation of specific 5-HT receptors evokes distinct, but highly interacting,

121 ling on GI motility was studied by examining 5-HT receptor expression in the colon and in vivo GI tra

122 study therefore provides a detailed atlas of 5-HT receptor expression within a well-characterized neu

123 integrated activity of at least 3 different 5-HT receptor families.

124 the most recently identified members of the 5-HT receptor family, and dendritic cells express this r

125 ocket is formed by residues conserved in the 5-HT receptor family, clarifying the family-wide agonist

126 ity and functional properties, including the 5-HT receptor family.

127 ide spectrum of human physiology through the 5-HT receptor family.

128 However, modification of 5-HT receptors following complete spinal cord injury res

129 binding with varying changes in postsynaptic 5-HT receptor function.

130 indicate that dimerization is essential for 5-HT receptor function.

131 Differences in certain 5-HT receptor functions may explain some of the clinical

132 Here we report five structures of 5-HT receptor-G-protein complexes: 5-HT(1A) in the apo s

133 trate that these ionotropic and metabotropic 5-HT receptors have a synergistic effect that is critica

134 Four distinct 5-HT receptors have been partially characterized, but li

135 5-HT receptors have high levels of basal activity and ar

136 esponses but the differing roles of the many 5-HT receptors have not been thoroughly investigated.

137 Although the MT(1) and 5-HT receptors have similar endogenous ligands, and agom

138 The 5-HT receptor immunolabeling was cytoplasmic, as with th

139 d that m-CPP did not appear to act through a 5-HT receptor in depressing neuronal function in the inv

140 osely match the affinity for the predominant 5-HT receptor in each region.

141 Our findings suggest the presence of a 5-HT receptor in mammalian salivary glands coupled to th

142 knowledge combinational action of SERT and a 5-HT receptor in SMC growth and Rho A/ROCK participation

143 ceptors suggested the presence of mRNA for a 5-HT receptor in these cells.

144 s 5-HT, confirming that MOD-1 functions as a 5-HT receptor in vivo.

145 ed cyclic nucleotide-gated (HCN) channels to 5-HT receptors in part mediates the excitatory effect of

146 repertoire of electrophysiologically active 5-HT receptors in prefrontal cortex is developmentally r

147 and alterations in the expression of several 5-HT receptors in the cortex, hippocampus, and hypothala

148 Our results indicate that post-synaptic 5-HT receptors in the developing hippocampus and cortex

149 udies, they support the presence of multiple 5-HT receptors in the mammalian retina and suggest that

150 HT receptors but is an intrinsic property of 5-HT receptors in vitro and ex vivo.

151 elinating rat Schwann cells normally express 5-HT receptors in vivo, and that receptor expression is

152 d reactivation of human 5-hydroxytryptamine (5-HT) receptors in a recombinant cell line.

153 nits form functional ligand-gated serotonin (5-HT) receptors in heterologous expression systems, it h

154 Among all described serotonin (5-HT) receptors in mammals, the type three (5-HT3) is th

155 00A10), a multifunctional protein binding to 5-HT receptors, in layer II/III neurons of the prelimbic

156 HT6 receptors are involved, along with other 5-HT receptors, in the pathophysiology and pharmacothera

157 Altered expression of other 5-HT receptors (including 5-HT(2) ) likely also contribu

158 y and depression are mediated by a number of 5-HT receptors, including autoreceptors that act to inhi

159 f the serotonin transporter and a variety of 5-HT receptors, including the 5-HT type-3 (5-HT3) recept

160 d, we demonstrate that, although presynaptic 5-HT receptors inhibit evoked neurotransmitter release f

161 Serotonin (5-HT) receptor interaction in the control of female rat

162 presence of a QD tag does not interfere with 5-HT receptor internalization or endosomal recycling.

163 adian activity rhythm; and (3) activation of 5-HT receptors is necessary for this DRN-stimulated circ

164 ing ChIs from the vSt by acting on different 5-HT receptor isoforms.

165 Of the 5-HT receptors known to be involved in proliferation, 5-

166 5-HT receptor labeling was observed in Schwann cells of

167 Serotonin (5-hydroxytryptamine; 5-HT) receptor ligands were used to assess agonist-stimu

168 , suggesting the hypophagia induced by these 5-HT receptors may be driven by different mechanisms.

169 This diverse action on 5-HT receptors may contribute to significant differences

170 ation of cAMP by different classes of DA and 5-HT receptors may contribute to the cell-type specifici

171 Serotonin (5-hydroxytryptamine, or 5-HT) receptors mediate a plethora of physiological phen

172 injection of 5-HT antagonists, indicating a 5-HT receptor-mediated pathway from the DRN to the SCN.

173 We show that 5-HT receptor-mediated presynaptic inhibition, at this s

174 in terms of the relative potency of 5-HT at 5-HT receptors mediating inhibition and facilitation of

175 etic outflow in a number of species, but the 5-HT receptors mediating these effects have yet to be fu

176 IL-4, IL-13, and 5-HT receptor messenger RNA expressions were determined

177 In the PFC, activated 5-HT receptors modify neuronal excitability and interact

178 Expression of 5-HT receptor mRNA was investigated in muscle strips, in

179 st affinity for several other populations of 5-HT receptors, notably h5-HT(1A) (K(i) = 170 nM), h5-HT

180 Because serotonergic interventions alter 5-HT receptor number in the hypothalamus, we asked wheth

181 mice, suggesting that the surface delineated 5-HT receptor on platelets may promote CMAH catalytic ac

182 are direct and are mediated via postsynaptic 5-HT receptors on motoneurons.

183 here has been no anatomical demonstration of 5-HT receptors on peripheral primary afferent processes.

184 Activation of the endogenous 5-HT receptors on pinealocytes evoked an intracellular C

185 Blocking 5-HT receptors once ON axons have crossed the chiasm doe

186 Loss of serotonin (5-hydroxytryptamine [5-HT]) receptors or of the serotonin transporter (SERT)

187 nal secretagogues, drugs acting on opioid or 5-HT receptors, or minimally absorbed antibiotics (all o

188 This review provides an overview of 5-HT receptor pharmacology and discusses two recent 5-HT

189 mitigating neurodevelopmental adaptations in 5-HT receptors plus compensatory alterations in 5-HT syn

190 will ultimately depend on the nature of the 5-HT receptors present over different parts of the posts

191 nal stimulation with agonists at subtypes of 5-HT receptors produces a beneficial interaction with tr

192 Previous studies showed that brainstem 5-HT receptor protein expression was abnormal in DBA/2 m

193 Therefore, expression of 5-HT receptor proteins in the medial-caudal brainstem of

194 crophages expressed the 5-HT transporter and 5-HT receptors (R) 2a, 2b, but not 2c.

195 resses 5-HT2A receptors (5-HT2ARs) and other 5-HT receptors, raising the possibility that the striata

196 gen psilocybin activates multiple serotonin (5-HT) receptors, recent evidence suggests that activatio

197 EB that are reversible by Gs protein-coupled 5-HT receptors responding to raphe-spinal activity, alth

198 Genetic manipulation of 5-HT receptors revealed that this neuromodulatory regula

199 .0microg), or received microinfusions of the 5-HT receptor-selective drugs 8-OH-DPAT (0.025 or 0.1mug

200 ibit egg laying in a manner dependent on the 5-HT receptor SER-1 and the G protein GOA-1.

201 We identified that two G-protein-coupled 5-HT receptors, SER-7 and SER-5, antagonistically regula

202 ceptor, OCTR-1, and a 5-HT1A-like serotonin (5-HT) receptor, SER-4, that involves a complex interacti

203 egeneration, suggesting a selective role for 5-HT receptor signaling early during ON regeneration.

204 ent Na+ channels are one potential target of 5-HT receptor signaling that have wide-ranging effects o

205 5-hydroxytryptamine (5-HT) receptor signaling potently inhibits excitatory po

206 The effect of 5-HT receptor-specific agonists and antagonists was exam

207 pirone is the 5-HT1A receptor, than the same 5-HT receptor sub-type at different locations (brain, ra

208 incipal cells via activation of two distinct 5-HT receptor subfamilies, 5-HT2A/2CR (5-HT2A/2C recepto

209 The 5-HT receptor subtype and signaling pathway that underli

210 In contrast, 5 did not alter levels of any 5-HT receptor subtype in any brain region examined.

211 of this study was to further identify which 5-HT receptor subtype mediates the enterostatin feeding

212 V)) 2.2 currents by 5-HT and to identify the 5-HT receptor subtype(s) mediating this response in acut

213 ceptor pharmacology and discusses two recent 5-HT receptor subtype-selective drugs, lorcaserin and pi

214 WAY-100635, an antagonist of the serotonin (5-HT) receptor subtype 5-HT1A were prepared.

215 the simultaneous activation of two distinct 5-HT receptor subtypes (5-HT7 and 5-HT2a) that have oppo

216 eus, the major source of 5-HT, and expresses 5-HT receptor subtypes (e.g., 5-HT2C and 5-HT1A) critica

217 We mapped binding at 5-HT receptor subtypes and transporters using quantitati

218 Multiple 5-HT receptor subtypes are expressed in the CA3 region o

219 Whether other 5-HT receptor subtypes are involved in the aetiology of

220 tle information is available on the specific 5-HT receptor subtypes expressed in primary afferents th

221 ly efficacious drugs that selectively target 5-HT receptor subtypes has been only occasionally succes

222 nally specific changes in binding to certain 5-HT receptor subtypes in obesity induced by voluntary o

223 This indicates that multiple 5-HT receptor subtypes in substantia nigra may contribut

224 ites, decreases food intake but the specific 5-HT receptor subtypes involved are controversial.

225 l raphe nucleus (DRN) and to determine which 5-HT receptor subtypes mediate these effects.

226 se to application of 5-HT, suggests that the 5-HT receptor subtypes on the motor neurons are analogou

227 Understanding the interactions between 5-HT receptor subtypes should lead to novel insights int

228 ne; however, the contributions of individual 5-HT receptor subtypes to the regulation of cocaine resp

229 Activation of different 5-HT receptor subtypes, specifically 5-HT(2) versus 5-HT

230 Expression of 14 5-HT receptor subtypes, the serotonin transporter (SERT)

231 efficacy and off-target binding at selected 5-HT receptor subtypes, where significant overlap in SAR

232 cells, reflecting the activation of distinct 5-HT receptor subtypes.

233 the presence of various ligands specific for 5-HT receptor subtypes.

234 uently due to nonspecific actions on various 5-HT receptor subtypes.

235 ansmission as a consequence of the number of 5-HT receptor subtypes.

236 Abnormalities of serotonin (5-HT) receptor subtypes have been observed in the postmo

237 sses several serotonin (5-hydroxytryptamine, 5-HT) receptor subtypes, including the 5-HT(1A) and 5-HT

238 Thus, mCPP interacts with distinct 5-HT receptor targets that produce opposing effects on l

239 b, had significantly higher affinity for the 5-HT receptors tested than did the benzodihydrofuran-con

240 er, the precise neural pathways and specific 5-HT receptors that account for its anorectic effect hav

241 Previously, four 5-HT receptors that contributed to the 5-HT modulation o

242 ) receptor is one of 14 different serotonin (5-HT) receptors that control neural function and behavio

243 e subtype of serotonin (5-hydroxytryptamine [5-HT]) receptor, the 5-HT(1A) receptor.

244 ugh both quipazine and TFMPP act on multiple 5-HT receptors, they overlap in their agonist action at

245 Furthermore, the ability of the activated 5-HT receptors to couple InsP3 synthesis was significant

246 f individual serotonin (5-hydroxytryptamine; 5-HT) receptors to mood control, we have used homologous

247 n nucleus, activation of a common serotonin (5-HT) receptor type, the 5-HT 1A receptor, depresses aud

248 of sensory afferent polarity may involve two 5-HT receptor types and that nociceptive and non-nocicep

249 .63 nM) and >300-fold selectivity over other 5-HT receptor types.

250 le groups of serotonin (5-hydroxytryptamine, 5-HT) receptors using single quantum dot (QD) probes and

251 he current investigation, desensitization of 5-HT receptors was demonstrated to inhibit the peristalt

252 Focusing on adrenergic (AR) and serotonin (5-HT) receptors, we found that adrenoceptor alpha 2C (Ad

253 Target 5-HT receptors were cloned and expressed in the HEK293 c

254 Although multiple 5-HT receptors were coexpressed in PFC pyramidal neurons

255 onal networks (HNNs) endogenously expressing 5-HT receptors were employed as sensing elements to buil

256 ory activity, and selectivity over a, o, and 5-HT receptors were evaluated.

257 Ligands of diverse 5-HT receptors were used to identify signaling pathway(s

258 In particular, serotonin (5-HT) receptors were shown to homodimerize and heterodim

259 signaling at the 5-HT2B 5-hydroxytryptamine (5-HT) receptor, whereas they are relatively unbiased at

260 In contrast, stimulation of 5-HT receptors with EMD 386088 caused a dose-dependent i

261 binds to the serotonin [5-hydroxytryptamine (5-HT)] receptor with relatively high affinity (Kd = 4.6

262 ird ventricle (AV3V) region, an area rich in 5-HT receptors, would attenuate increases in blood press

263 herapeutic agents, while their comparison to 5-HT receptors yields insights into the evolution and po